Skip to content
Contact us
Essential Podcast Logo
Join us each month on Essential for the latest in compounding pharmacy — breaking down news, trends, and what it all means for you. Smart, insightful, and just a little nerdy.

 

Episode 6: The Compounding AI Primer Episode

 
          This month, we look at a somewhat confusing, possibly problematic FDA statement, as well as the anti-compounding bills popping up across the country. Our Deep Dive this week is a hot topic: AI in pharmacies — how it’s being used successfully, but also how you can use it to streamline your workflow and, yes, even increase your bottom line. Our expert will tell you what to look for, and what easy pitfall you need to avoid.    
 
The troublesome FDA statement: https://fllw.me/4utzQIw
 
APC’s Snapshot of Pharmacy Compounding: https://a4pc.org/snapshot
 
Read more about the 2002 Supreme Court case "Thompson v. Western States Medical Center": https://www.oyez.org/cases/2001/01-344
 
 

 

Episode 5: Peddling a Fantasy: How Drugmakers are Misleading State Lawmakers

 
   In this edition of Essential, we look at two major issues facing pharmacy compounding. First is a state-by-state effort by pharma companies to
pass laws restricting compounding, and second is a cryptic statement from the FDA about possible limitations on compounding with GLP-1 ingredients. They’re both Very Big Deals for pharmacists across the country.      
 
 
 
Stay up to date on our state Compounding Defense Initiative: compounding.com
 
 
Find us on social:  
 
 

 

Episode 4: The Peptide Problem

 
  In this edition of Essential, we’ve got concerns about the FDA’s revolving door, some issues with a new California law that might affects the
    whole country, and a new accreditation that might save a lot of headache. Then we take a deep dive into the once and future world of
compounded peptides — where they are, and where they might be going … and why.    
 
FDA’s revolving door: https://archive.ph/oxBXP
   
 
 

 

Episode 3: The Mythbusting Episode

 
    In this edition of Essential, we’ve got updates on some big compounding news — like the FDA’s long-overdue decision to remove the
  boxed warning from some menopause hormone-replacement therapy drugs. (And yes, that’s important for compounding pharmacists!)  
    We also look at the hubbub at FDA over what (allegedly) was behind the decision that would have effectively banned compounding with desiccated thyroid extract, plus some stories from the states, and more.  
 
  This month’s deep dive: Mythbusting, compounded-GLP-1 style! What have the big drugmakers been saying, and how much of it is true? They’re spreading stories, but our experts put them to the test. Don’t miss out!  
   
 
FDA to remove boxed warning from HRT medications: https://archive.ph/R8DJD  
 
An example of what appears to be an op-ed pushed by a pharma company. The writer, a “former healthcare professional,” doesn’t appear to exist: https://archive.ph/OPNWr    
 
Find a legitimate, licensed compounding pharmacy: https://a4pc.org/isitlegit    
 
Benefits of becoming an APC PFM: https://a4pc.org/pfm 

 

Episode 2: Lies and Lawsuits

 
  In this edition of Essential, we look at how we’re pushing back against the FDA’s upcoming ban on desiccated thyroid extract, why drugmakers’ latest tactics against compounding pharmacies are backfiring, and we give you a great way to make sure your practice is performing at its best.
 
 Then we take a deep dive with attorney and pharmacist Mark Boesen into the lawsuits being filed against compounding pharmacies, what the results have been, and how they might affect more than just pharmacy in the future.

Boesen & Snow Law: https://www.boesensnowlaw.com/

“FDA’s confusing warning letters": (https://a4pc.org/news/fdas-confusing-warning-letters)

“FDA’s green list: Not our problem?": (https://a4pc.org/news/fdas-green-list-not-our-problem)

APC's Best Practices documents: a4pc.org/bestpractices

National Review article on FDA crackdown: https://archive.ph/LYy7t

 

Episode 1: The DTE Mess, Pharmacy Board Shenanigans, and GLP-1 Confusion 

 
   This edition of Essential unpacks FDA confusion, California’s latest compounding curveball, and pharma-fueled myths about GLP-1s.
We spotlight APC’s advocacy wins on Capitol Hill and why pharmacy tours pack political punch. Plus, the FDA’s eyebrow-raising move to reclassify natural thyroid products — and why it matters for patients everywhere.
 
 
 
 
 
DTE grassroots campaign: https://compounding.com/thyroid